Translocation Mechanism in Secondary Leukemias Following Topoisomerase II Poisons

Published: June 16, 2009
Abstract Views: 311
PDF: 401
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

More than 15 years after observations of an association between a distinct form of leukemia characterized by balanced chromosomal translocations involving band 11q23 and introduction of epipodophyllotoxins into clinical usage for anti-cancer treatment in the late1980s, the translocation mechanism is still debated. Epipodophyllotoxins and other anticancer drugs that have been linked to leukemias with various balanced translocations as a treatment complication share the property of being topoisomerase II poisons. In the early 1990s the MLL (ALL-1, HRX, hTRX1) gene was cloned by several groups at the genomic breakpoint junctions of translocations disrupting chromosome band 11q23. This paper will review evidence in favor of the hypothesis that topoisomerase II cleavage complexes induced by poisons of this enzyme damage DNA directly and lead to translocations in secondary leukemias with MLL translocations.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Felix, C. A., Robinson, B. W., Germano, G., Kolaris, C. P., Raffini, L. J., Lo Nigro, L., Roumm, E., Megonigal, M. D., Slater, D. J., Whitmarsh, R. J., Saginario, C., Lovett, B. D., Libura, J., & Pegram, L. D. (2009). Translocation Mechanism in Secondary Leukemias Following Topoisomerase II Poisons. Hematology Meeting Reports (formerly Haematologica Reports), 2(15). https://doi.org/10.4081/hmr.v2i15.600